In the clinical context, rosiglitazone, a PPARγ agonist used for diabetes, has been associated with various adverse effects, including lactic acidosis, cardiac failure, and weight gain, highlighting the need for transparency in adverse event reporting to ensure a thorough understanding and assessment of drug safety profiles. The gene discussed is PPARG; the disease is heart failure.